leisure time -WSS

leisure time

author：entertainment 2025-08-12 09:12:42 - browse：5415

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Researchers test human milk's ability to repair gut microbiome

explore

WSS

Scientists uncover potential path to treating deadly childhood tumor

Harvard scientists, with Google, unveil the most detailed brain map ever

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Mass General, Mayo Clinic look to monetize custom

Dana Farber says 6 studies to be retracted and 31 corrected

TikTok, Instagram influencers need more rules for drug ads

leisure time

leisure time

The next ALS data readout — overdue but important

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Inaction leaves children at risk from dangerous chemotherapy drug

Virginia high school admissions case could be legal follow

Future doctors need a strong humanities education

Duchenne breakthrough therapy leaves behind pioneering families

Covid silver lining: Unprecedented look at human immune system

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare Advantage 2025 payments will dip, Biden administration says

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA endorses new sterilization method for medical devices

knowledge

Hundreds died while taking an arthritis drug, but nobody alerted patients

Cardiologists urge adding sexual orientation, gender identity to health records

U.K. decision on ALS drug has neurologists, advocates up in arms

Maisha Meds is a PBM, but don't call it that

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Harvard scientists, with Google, unveil the most detailed brain map ever

entertainment

hotspot

explore

hotspot